Center for Cranial Nerve Disorders, Department of Neurosurgery, Allegheny General Hospital, Allegheny Neuroscience Institute/Drexel University College of Medicine, Pittsburgh, Pennsylvania 15212, USA.
J Neurosurg. 2011 Jan;114(1):172-9. doi: 10.3171/2010.6.JNS10142. Epub 2010 Jul 23.
Because the incidence of trigeminal neuralgia (TN) increases with age, neurosurgeons frequently encounter elderly patients with this disorder. Although microvascular decompression (MVD) is the only etiological therapy for TN with the highest initial efficacy and durability of all treatments, it is nonetheless associated with special risks (cerebellar hematoma, cranial nerve injury, stroke, and death) not seen with the commonly performed ablative procedures. Thus, the safety of MVD in the elderly remains a concern. This prospective study and systematic review with meta-analysis was conducted to determine whether MVD is a safe and effective treatment in elderly patients with TN.
In this prospectively conducted analysis, 36 elderly patients (mean age 73.0 ± 5.9 years) and 53 nonelderly patients (mean age 52.9 ± 8.8 years) underwent MVD over the study period. Outcome and complication data were recorded. The authors also conducted a systematic review of the English literature published before December 2009 and providing outcomes and complications of MVD in patients with TN above the age of 60 years. Pooled complication rates of stroke, death, cerebellar hematoma, and permanent cranial nerve deficits were analyzed.
Thirty-one elderly patients (86.1%) reported an excellent outcome after MVD (mean follow-up 20.0 ± 7.0 months). Twenty-five elderly patients with Type 1 TN were compared with 26 nonelderly patients with Type 1 TN, and no significant difference in outcomes was found (p = 0.046). Three elderly patients with Type 2a TN were compared with 12 nonelderly patients with Type 2a TN, and no significant difference in outcomes was noted (p = 1.0). Eight elderly patients with Type 2b TN were compared with 15 nonelderly patients with Type 2b TN, and no significant difference in outcomes was noted (p = 0.086). The median length of stay between cohorts was compared, and no significant difference was noted (2 days for each cohort, p = 0.33). There were no CSF leaks, no cerebellar hematomas, no strokes, and no deaths. Eight studies (1334 patients) met the inclusion criteria for the meta-analysis. For none of the complications was the incidence significantly more frequent in elderly patients than in the nonelderly.
Although patient selection remains important, the authors' experience and the results of this systematic review with meta-analysis suggest that the majority of elderly patients with TN can safely undergo MVD.
由于三叉神经痛(TN)的发病率随年龄增长而增加,神经外科医生经常会遇到患有这种疾病的老年患者。尽管微血管减压术(MVD)是唯一针对 TN 的病因治疗方法,其初始疗效和持久性在所有治疗方法中最高,但它也与通常进行的消融手术不同,存在特殊风险(小脑血肿、颅神经损伤、中风和死亡)。因此,MVD 在老年人中的安全性仍然是一个关注点。这项前瞻性研究和系统评价及荟萃分析旨在确定 MVD 是否是老年 TN 患者的一种安全有效的治疗方法。
在这项前瞻性分析中,36 名老年患者(平均年龄 73.0 ± 5.9 岁)和 53 名非老年患者(平均年龄 52.9 ± 8.8 岁)在研究期间接受了 MVD 治疗。记录了结果和并发症数据。作者还对 2009 年 12 月前发表的英文文献进行了系统评价,并提供了年龄在 60 岁以上的 TN 患者 MVD 的结果和并发症。分析了中风、死亡、小脑血肿和永久性颅神经缺陷的汇总并发症发生率。
31 名老年患者(86.1%)在 MVD 后报告了良好的结果(平均随访 20.0 ± 7.0 个月)。25 名 1 型 TN 老年患者与 26 名非老年 1 型 TN 患者进行比较,结果无显著差异(p = 0.046)。3 名 2a 型 TN 老年患者与 12 名非老年 2a 型 TN 患者进行比较,结果无显著差异(p = 1.0)。8 名 2b 型 TN 老年患者与 15 名非老年 2b 型 TN 患者进行比较,结果无显著差异(p = 0.086)。比较了两组患者的中位住院时间,无显著差异(每组住院 2 天,p = 0.33)。没有发生脑脊液漏、小脑血肿、中风或死亡。8 项研究(1334 名患者)符合荟萃分析的纳入标准。在所有并发症中,老年患者的发生率均无明显高于非老年患者。
尽管患者选择仍然很重要,但作者的经验和系统评价及荟萃分析的结果表明,大多数老年 TN 患者可以安全地接受 MVD。